Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03484299
PHASE1

Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Sponsor: University of Louisville

View on ClinicalTrials.gov

Summary

Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.

Official title: Chemotherapy and Irreversible Electroporation (IRE) in the Treatment of Advanced Pancreatic Adenocarcinoma

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2018-05-30

Completion Date

2027-07-31

Last Updated

2025-10-29

Healthy Volunteers

No

Conditions

Interventions

PROCEDURE

Irreversible Electroporation (IRE)

Non-thermal ablation of tumor

DRUG

Gemcitabine

25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled

DRUG

FOLFIRINOX

25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled

Locations (1)

University of Louisville

Louisville, Kentucky, United States